2 results
Approved WMOCompleted
To provide proof of concept that POWER2DM is safe and effective in improving glycaemic control and analyse of the cost-effectiveness of the approach to highlight any potential issues that may impede implementation.
Approved WMORecruiting
Primary Part 1:-To evaluate ORR in participants treated with MK-4280A plus EV (Arm A), MK-7684A plus EV (Arm B), and pembrolizumab plus EV(Arm C) per RECIST 1.1 by BICR.- To evaluate the safety and tolerability in participants treated with MK-4280A…